A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN) Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Conditions

Lung

Phase I

Volunteers
Health Professionals

What is the purpose of this trial?

To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult subjects with KRAS p.G12C mutant advanced solid tumors.

Find out more about who can participate in this trial

Trial with
Amgen, Inc.
Start Date
01/14/2022
End Date
12/15/2021

For more information about this study, contact:

Kira Fitzsimons Pavlik

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Sarah Goldberg, MD, MPH
Associate Professor of Internal Medicine (Medical Oncology); Associate Director, Hematology/Oncology Fellowship Program; Research Director, Center for Thoracic Cancers

Sub-Investigators

Last Updated
01/17/2022
Study HIC
#2000026544

A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN) Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigators

Contact Information